Tiludronate disodium hemihydrate is used in the study of metabolic bone diseases; it acts as a potent inhibitor of osteoclast vacuolar H⁺-ATPase, thereby inhibiting bone resorption in a dose-dependent manner; it reduces the capacity of mature osteoclasts to secrete protons into the resorption space and promotes their detachment from the bone matrix; it has been tested in other osteoporosis models, such as the castrated male rat model, where it prevents the decrease in skeletal mass, as assessed by bone weight, density, and calcium and phosphate content.